Research programme: microRNA-targeted therapeutics - Rosetta Genomics

Drug Profile

Research programme: microRNA-targeted therapeutics - Rosetta Genomics

Alternative Names: miR-34a therapeutics - Rosetta/Weizmann Institute

Latest Information Update: 28 Sep 2015

Price : $50

At a glance

  • Originator Rosetta Genomics
  • Developer Rosetta Genomics; Weizmann Institute of Science
  • Class Antisense oligonucleotides
  • Mechanism of Action RNA inhibitors; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Sep 2015 Rosetta Genomics receives patent allowance for anti-hsa-miR-210 for the treatment of Prostate cancer in USA
  • 29 Apr 2015 European Patent Office upheld European Patent No. 2 126 078 granted to Rosetta Genomics for the use of miR-34a for the preparation of pharmaceuticals for treating p53-negative cancers
  • 01 Feb 2015 Rosetta receives patent allowance for the therapeutic use of miR-34a for the treatment of any p53-associated cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top